Etrasimod

81 interactions 4 explained in plain English

Also sold as: Velsipity

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 4, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Oxaliplatin Injection Sertraline Fluorouracil Injection Degarelix Injection Octreotide Injection Bedaquiline

63 Major 18 Moderate

All (81) Major (63) Moderate (18)

Major

Etrasimod Amitriptyline Elavil Explained Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Etrasimod Sertraline Explained Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Etrasimod Buprenorphine Belbuca Explained Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Etrasimod Amisulpride Injection Barhemsys Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Etrasimod Arsenic Trioxide Trisenox Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Etrasimod Aripiprazole Injection Abilify Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Etrasimod Arsenic Trioxide Injection Trisenox Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Etrasimod Asenapine Transdermal Patch Secuado Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Etrasimod Azithromycin AzaSite Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Etrasimod Alfuzosin UroXatral Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Etrasimod Anagrelide Agrylin Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Etrasimod Bedaquiline Sirturo Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Etrasimod Capecitabine Xeloda Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Etrasimod Chloroquine Aralen® Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Etrasimod Dasatinib Phyrago Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Etrasimod Degarelix Injection Firmagon Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Etrasimod Deutetrabenazine Austedo Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Etrasimod Disopyramide Norpace Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Etrasimod Dofetilide Tikosyn Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Etrasimod Dolasetron Anzemet Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Etrasimod Dolasetron Injection Anzemet Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Etrasimod Encorafenib Braftovi Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Etrasimod Entrectinib Rozlytrek Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Etrasimod Eribulin Injection Halaven Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Etrasimod Famotidine Calmicid Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Etrasimod Famotidine Injection Calmicid Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Etrasimod Felbamate Felbatol Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Etrasimod Flecainide Tambocor® Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Etrasimod Fluorouracil Adrucil Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Etrasimod Fluorouracil Injection Adrucil Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Etrasimod Fluorouracil Topical Carac Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Etrasimod Foscarnet Injection Foscavir Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Etrasimod Galantamine Razadyne Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Etrasimod Gatifloxacin Ophthalmic Zymar® Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Etrasimod Gemifloxacin Factive Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Etrasimod Glasdegib Daurismo Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Etrasimod Goserelin Implant Zoladex Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Etrasimod Granisetron Transdermal Patch Sancuso Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Etrasimod Granisetron Injection Granisol Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Etrasimod Histrelin Implant Supprelin Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.